Literature DB >> 22949455

Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs.

Shailender Swaminathan1, Vincent Mor, Rajnish Mehrotra, Amal Trivedi.   

Abstract

Since 1973 Medicare has provided health insurance coverage to all people who have been diagnosed with end-stage renal disease, or kidney failure. In this article we trace the history of payment policies in Medicare's dialysis program from 1973 to 2011, while also providing some insight into the rationale for changes made over time. Initially, Medicare adopted a fee-for-service payment policy for dialysis care, using the same reimbursement standards employed in the broader Medicare program. However, driven by rapid spending growth in this population, the dialysis program has implemented innovative payment reforms, such as prospective bundled payments and pay-for-performance incentives. It is uncertain whether these strategies can stem the increase in the total cost of dialysis to Medicare, or whether they can do so without adversely affecting the quality of care. Future research on the intended and unintended consequences of payment reform will be critical.

Entities:  

Mesh:

Year:  2012        PMID: 22949455      PMCID: PMC3766315          DOI: 10.1377/hlthaff.2012.0368

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  25 in total

1.  The quality of health care delivered to adults in the United States.

Authors:  Elizabeth A McGlynn; Steven M Asch; John Adams; Joan Keesey; Jennifer Hicks; Alison DeCristofaro; Eve A Kerr
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  Pay-for-performance: the MedPAC perspective.

Authors:  Karen Milgate; Sharon Bee Cheng
Journal:  Health Aff (Millwood)       Date:  2006 Mar-Apr       Impact factor: 6.301

3.  Bundled payment for ESRD--including ESAs in Medicare's dialysis package.

Authors:  John K Iglehart
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

4.  Fitness memberships and favorable selection in Medicare Advantage plans.

Authors:  Alicia L Cooper; Amal N Trivedi
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

5.  Comparative mortality risk of anemia management practices in incident hemodialysis patients.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Jerry Avorn; Brian D Bradbury; Jun Liu; Wolfgang C Winkelmayer
Journal:  JAMA       Date:  2010-03-03       Impact factor: 56.272

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

7.  Association of hemoglobin and survival in peritoneal dialysis patients.

Authors:  Miklos Z Molnar; Rajnish Mehrotra; Uyen Duong; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

8.  Medicare program; end-stage renal disease prospective payment system. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2010-08-12

9.  Medicare's end-stage renal disease program: current status and future prospects.

Authors:  A R Nissenson; R A Rettig
Journal:  Health Aff (Millwood)       Date:  1999 Jan-Feb       Impact factor: 6.301

10.  Cost savings and physician responses to global bundled payments for Medicare heart bypass surgery.

Authors:  J Cromwell; D A Dayhoff; A H Thoumaian
Journal:  Health Care Financ Rev       Date:  1997
View more
  23 in total

1.  Efficiency of U.S. dialysis centers: an updated examination of facility characteristics that influence production of dialysis treatments.

Authors:  Sanatan Shreay; Martin Ma; Jill McCluskey; Ron C Mittelhammer; Matthew Gitlin; J Mark Stephens
Journal:  Health Serv Res       Date:  2013-11-18       Impact factor: 3.402

2.  Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents.

Authors:  Shailender Swaminathan; Vincent Mor; Rajnish Mehrotra; Amal N Trivedi
Journal:  Health Serv Res       Date:  2014-10-30       Impact factor: 3.402

3.  Research Priorities in Subspecialty Palliative Care: Policy Initiatives.

Authors:  Lynn F Reinke; Diane E Meier
Journal:  J Palliat Med       Date:  2017-08       Impact factor: 2.947

4.  Home Dialysis in the Prospective Payment System Era.

Authors:  Eugene Lin; Xingxing S Cheng; Kuo-Kai Chin; Talhah Zubair; Glenn M Chertow; Eran Bendavid; Jayanta Bhattacharya
Journal:  J Am Soc Nephrol       Date:  2017-05-10       Impact factor: 10.121

5.  ESRD Payment Reform: First Do No Harm.

Authors:  Jenny I Shen; Keith C Norris
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

Review 6.  Palliative Care Disincentives in CKD: Changing Policy to Improve CKD Care.

Authors:  Manjula Kurella Tamura; Ann M O'Hare; Eugene Lin; Laura M Holdsworth; Elizabeth Malcolm; Alvin H Moss
Journal:  Am J Kidney Dis       Date:  2018-03-03       Impact factor: 8.860

7.  Understanding Trends in Medicare Spending, 2007-2014.

Authors:  Laura M Keohane; Robert J Gambrel; Salama S Freed; David Stevenson; Melinda B Buntin
Journal:  Health Serv Res       Date:  2018-03-06       Impact factor: 3.402

8.  The Affordable Care Act, Medicaid Expansion, and Disparities in Kidney Disease.

Authors:  Amal N Trivedi; Benjamin D Sommers
Journal:  Clin J Am Soc Nephrol       Date:  2017-12-14       Impact factor: 8.237

Review 9.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

Review 10.  Outpatient Dialysis for Patients with AKI: A Policy Approach to Improving Care.

Authors:  Michael Heung; Sarah Faubel; Suzanne Watnick; Dinna N Cruz; Jay L Koyner; Girish Mour; Kathleen D Liu; Jorge Cerda; Mark D Okusa; Mark Lukaszewski; Anitha Vijayan
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.